Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, chromophobe renal cell carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, papillary renal cell carcinoma, renal cell carcinoma, renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions, sarcomatoid renal cell carcinoma, urinary system disorder	Active, not recruiting	Phase 2	2026-07-16		NCT03541902

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Exelixis	77
M.D. Anderson Cancer Center	1145
National Cancer Institute (NCI)	3015

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
M D Anderson Cancer Center	Houston	United States	667
MD Anderson Regional Care Center-Katy	Houston	United States	7
MD Anderson Regional Care Center-Sugar Land	Sugar Land	United States	7